CXCL8 and melanoma: Because IL8 was previously shown to be expressed in higher levels in patients that progressed from II to stage III melanoma (23), it is a poor prognostic marker in stage IV melanoma, and a decrease in levels from baseline are correlated with response to anti-PD-1 treatment (25), an anti-IL8 antibody (HuMax-IL8, BMS-986253) has been developed.